Tolero Pharmaceuticals submits investigational new drug application for experimental PKM2 a ctivator TP-1454

This article was originally published here

Under this IND, Tolero intends to conduct a Phase 1/1b, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic and pharmacodynamic study, which will evaluate oral TP‑1454 alone, and in combination with

The post Tolero Pharmaceuticals submits investigational new drug application for experimental PKM2 a ctivator TP-1454 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply